A5002176491- Tuberculosis Research and Epidemiology
- HIV/AIDS Research and Interventions
- Pneumocystis jirovecii pneumonia detection and treatment
- HIV/AIDS drug development and treatment
- Cystic Fibrosis Research Advances
- Pharmaceutical studies and practices
- Pregnancy and Medication Impact
- Pneumonia and Respiratory Infections
- Epilepsy research and treatment
- Pharmacological Effects and Toxicity Studies
- Global Maternal and Child Health
Infectious Diseases Research Collaboration
2021-2025
Background Expanding access to shorter regimens for tuberculosis (TB) prevention, such as once-weekly isoniazid and rifapentine taken 3 months (3HP), is critical reducing global TB burden among people living with HIV (PLHIV). Our coprimary hypotheses were that high levels of acceptance completion 3HP could be achieved delivery strategies optimized overcome well-contextualized barriers would highest when PLHIV provided an informed choice between strategies. Methods findings In a pragmatic,...
Little is known about how people living with HIV would choose if offered different tuberculosis preventive treatment (TPT) regimens, and under which conditions they accept treatment. Actionable evidence regarding preference for TPT needed to inform policy the development of novel regimens. Adults engaged in care at an clinic Kampala, Uganda, completed a discrete choice experiment survey nine random tasks. In each task, participants first chose between two hypothetical regimens differing...
<sec id="st1"><title>BACKGROUND</title>Both 1 month of daily (1HP) and 3 months weekly (3HP) isoniazid-rifapentine are recommended as short-course regimens for TB prevention among people living with HIV (PLHIV). We aimed to assess acceptability preferences 1HP vs. 3HP PLHIV.</sec><sec id="st2"><title>METHODS</title>In a cross-sectional survey PLHIV at an clinic in Kampala, Uganda, participants were randomly assigned hypothetical scenario receiving or...
Abstract Introduction Tuberculosis (TB) preventive treatment (TPT) is recommended for people living with HIV (PLHIV) in high TB burden settings. While 6 months of daily isoniazid remains widely used, shorter regimens are now available. However, little known about preferences PLHIV key features TPT regimens. Methods From July to November 2022, we conducted a discrete choice experiment among adult engaged care at an urban clinic Kampala, Uganda. Participants chose between two hypothetical five...
Background Scaling up shorter regimens for tuberculosis (TB) prevention such as once weekly isoniazid–rifapentine (3HP) taken 3 months is a key priority achieving targets set forth in the World Health Organization’s (WHO) END TB Strategy. However, there are few data on 3HP patient acceptance and completion context of routine HIV care sub-Saharan Africa. Methods findings The Options Trial pragmatic, parallel type effectiveness–implementation randomized trial comparing optimized strategies...
Three months of isoniazid-rifapentine (3HP) is being scaled up for tuberculosis (TB) preventive treatment (TPT) among people living with HIV (PLHIV) in high-burden settings. More evidence needed to identify factors influencing successful 3HP delivery. We conducted a qualitative assessment delivery nested within the Options Trial, which compared three optimized strategies delivering 3HP: facilitated directly observed therapy (DOT), self-administered (SAT), and patient choice between DOT SAT...
Abstract Background Short-course tuberculosis (TB) prevention regimens, including 12 weeks of isoniazid and rifapentine (3HP), are increasingly used in high-TB-burden countries. Despite established safety tolerability efficacy trials, 3HP-related adverse events (AEs) could differ routine settings. Real-world data on AE type, frequency, timing crucial for health systems considering 3HP programmatic scale-up. Methods We reviewed AEs among people with human immunodeficiency virus (HIV)...
Short-course tuberculosis (TB) prevention regimens, including 12 weeks of isoniazid and rifapentine (3HP), are increasingly used in high TB-burden countries. Despite established safety tolerability efficacy trials, 3HP-related adverse events (AE) could differ routine settings. Real-world data on AE type, frequency, timing is crucial for health systems considering 3HP programmatic scale-up. We reviewed AEs among people living with HIV (PLHIV) participating a pragmatic implementation trial...
Three months of isoniazid-rifapentine (3HP) is being scaled up for tuberculosis (TB) preventive treatment (TPT) among people living with HIV (PLHIV) in high-burden settings. More evidence needed to identify factors influencing successful 3HP delivery. We conducted a qualitative assessment delivery nested within the Options Trial, which compared three optimized strategies delivering 3HP: facilitated directly observed therapy (DOT), self-administered (SAT), and patient choice between DOT SAT...
BACKGROUND: Twelve weeks of weekly isoniazid and rifapentine (3HP) prevents TB disease among people with HIV (PWH), but the costs to taking preventive treatment is not well described. METHODS: We surveyed PWH who initiated 3HP at a large urban HIV/AIDS clinic in Kampala, Uganda, as part larger trial. estimated cost one visit from patient perspective, including both out-of-pocket lost wages. Costs were reported 2021 Ugandan shillings (UGX) US dollars (USD; USD1 = UGX3,587) RESULTS: The survey...
Abstract Background Tuberculosis (TB) preventive treatment (TPT) is recommended for people living with HIV (PLHIV) in high TB burden settings. While 6 months of daily isoniazid remains widely used, shorter regimens are now available. However, little known about preferences PLHIV key features TPT regimens. Methods We conducted a discrete choice experiment among adult engaged care at an urban clinic Kampala, Uganda. In nine random tasks, participants chose between two hypothetical different...
Background: Expanding access to shorter regimens for tuberculosis (TB) prevention, such as once-weekly isoniazid and rifapentine taken three months (3HP), is critical reducing global TB burden among people living with HIV (PLHIV).Methods: In a pragmatic, three-arm, parallel-group randomized trial, PLHIV receiving care at large urban clinic in Kampala, Uganda, were randomly assigned (1:1:1) receive 3HP by facilitated directly observed therapy (DOT), self-administered (SAT), or informed choice...